<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacoepidemiology and drug safety</journal-title></journal-title-group><issn pub-type="ppub">1053-8569</issn><issn pub-type="epub">1099-1557</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10766437</article-id><article-id pub-id-type="pmcid-ver">PMC10766437.1</article-id><article-id pub-id-type="pmcaid">10766437</article-id><article-id pub-id-type="pmcaiid">10766437</article-id><article-id pub-id-type="manuscript-id">NIHMS1949712</article-id><article-id pub-id-type="pmid">36760024</article-id><article-id pub-id-type="doi">10.1002/pds.5596</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1949712</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1949712</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Dopamine Agonists and Risk of Lung Cancer in Patients with Restless Legs Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4959-9141</contrib-id><name name-style="western"><surname>Hernandez-Con</surname><given-names initials="P">Pilar</given-names></name><degrees>MD, MSCE</degrees><aff id="A1">Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, Gainesville, Florida 32610, USA</aff><aff id="A2">Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0266-0980</contrib-id><name name-style="western"><surname>Shults</surname><given-names initials="J">Justine</given-names></name><degrees>PhD</degrees><aff id="A3">Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA</aff><aff id="A4">Roberts Center for Pediatric Research, Children&#8217;s Hospital of Philadelphia, PA 19146, USA.</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5724-7192</contrib-id><name name-style="western"><surname>Willis</surname><given-names initials="AW">Allison W.</given-names></name><degrees>MD, MS</degrees><aff id="A5">Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA</aff><aff id="A6">Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3690-9174</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="YX">Yu-Xiao</given-names></name><degrees>MD, MSCE</degrees><aff id="A7">Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA</aff><aff id="A8">Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA</aff></contrib></contrib-group><author-notes><corresp id="CR1">Corresponding author: Yu-Xiao Yang, MD, MSCE, Address: Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Drive, 733 Blockley Hall, Philadelphia, PA 19104, USA., Tel: + 1-215-573-5027, <email>yangy@pennmedicine.upenn.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P25">Conflicts of Interest</p><p id="P26">The authors declare that they have no conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2023</year></pub-date><volume>32</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">452403</issue-id><fpage>726</fpage><lpage>734</lpage><pub-history><event event-type="nihms-submitted"><date><day>16</day><month>12</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>04</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>04</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 16:25:15.287"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1949712.pdf"/><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P1">To examine the association between long-term use of dopamine agonists (DAs) and the risk of lung cancer in patients with restless legs syndrome (RLS).</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We conducted a retrospective cohort study using Optum Clinformatics<sup>&#174;</sup> database. We included adults &#8805; 40 years diagnosed with RLS during the study period (1/2006 &#8211; 12/2016). Follow-up started with the first RLS diagnosis and ended on the earliest of: incident diagnosis of lung cancer, end of enrollment in the database or end of the study period. The exposure of interest was cumulative duration of DAs use, measured in a time-varying manner. We constructed a multivariable Cox regression model to estimate HRs and 95% CIs for the association between lung cancer and cumulative durations of DA use, adjusting for potential confounding variables.</p></sec><sec id="S3"><title>Results:</title><p id="P3">We identified 295,042 patients with a diagnosis of RLS. The mean age of the cohort was 62.9; 66.6% were women and 82.3% were white. The prevalence of any DA exposure was 40.3%. Compared to the reference group (no use and &#8804; 1 year), the crude HRs for lung cancer were 1.16 (95%CI 0.99 &#8722;1.36) and1.14 (95% CI 0.86 &#8722;1.51) for 1&#8211;3 years and &gt; 3 years of cumulative DA use, respectively. The adjusted HR for lung cancer was 1.05 (95% CI 0.88&#8211;1.25) for 1&#8211;3 years and 1.02 (95% CI 0.76&#8211;1.37) for &gt; 3 years of cumulative DA use, respectively.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">At typical doses for the clinical management of RLS, long-term DA use was not associated with risk of lung cancer.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Plain Language Summary</title><p id="P5">Lung cancer is the leading cause of cancer-related deaths worldwide despite the advent of new treatment options. Preclinical evidence suggests that dopamine agonists (DAs), first-line therapy for restless legs syndrome (RLS), may have anti-tumor activity in lung. The effect of DAs (i.e., pramipexole, ropinirole and rotigotine) on lung cancer in humans remains unclear. This retrospective cohort study examined the association between long-term use of DAs and the risk of lung cancer in patients with RLS, using commercial claims data, from January 1, 2006, through December 31<sup>st</sup>, 2016. We estimated the risk of developing lung cancer associated with the cumulative exposure to DAs (analyzed as a time-varying variable) among adults 40 years and older with a diagnosis of RLS, using a multivariable Cox regression model, adjusting for age, sex and other variables of interest. We identified 295,042 patients with RLS; the majority of them were women and white and had a mean age of 62.9 years. We did not find an association between long-term cumulative use of DAs (&gt; 1 year) and lung cancer compared to non-use or shorter-term use (&#8804; 1 year) of cumulative use of DAs.</p></abstract><kwd-group><kwd>RLS</kwd><kwd>dopamine agonists</kwd><kwd>lung cancer</kwd><kwd>time-varying exposure</kwd><kwd>epidemiology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>